Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ertumaxomab in hormone therapy refractory HER2-low advanced or metastatic breast cancer
2005-004294-21Phase 2Completed
- Sponsor
- Fresenius
- Start
- Nov 2005
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ertumaxomab in breast cancer, sponsored by Fresenius. Primary endpoint: Objective response rate. Started Nov 2005; status: completed.
02
Drugs
ertumaxomab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004294-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004294-21.